Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali Volume 6 Issue 1 (2025)
REVIEW OF CLINICAL TRIALS WITH SODIUM GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS
Ахмедова Д.Т, Алимова Д.А, Тригулова Р.Х
Abstract
This review article summarizes and analyzes clinical trials assessing the efficacy and safety of SGLT2 inhibitors, a class of drugs used primarily for the treatment of Type 2 diabetes mellitus. The review covers several key studies, including the EMMY, EMPAREG OUTCOME, DAPA-HF, EMPULSE, SOLOIST-WHF and EMPACT-MI trials, highlighting the positive impact of SGLT2 inhibitors on reducing cardiovascular events and improving kidney outcomes. The article further discusses the expansion of SGLT2 inhibitors' use beyond diabetes treatment to address heart failure and chronic kidney disease. The authors conclude that SGLT2 inhibitors offer significant benefits in managing type 2 diabetes mellitus and related complications, while also demonstrating promise in broader therapeutic areas. This review is essential for understanding the evolving role of SGLT2 inhibitors in modern clinical practice and provides valuable insights into ongoing research. It is particularly relevant to my study on the cardiovascular benefits of medications and their long-term effects.
Ингибиторы SGLT2, антиремоделирующий эффект, сердечная недостаточность, инфаркт миокарда, хроническая болезнь почек, скорость клубочковой фильтрации, антигипергликемический эффектSGLT2 inhibitors, antiremodeling effect, heart failure, myocardial infarction, chronic kidney disease, glomerular filtration rate, antihyperglycemic effectSGLT2 ingibitorlari, antiremodelirlanuvchi ta'siri, yurak etishmovchiligi, miokard infarkti, surunkali buyrak kasalligi, glomerulyar filtratsiya tezligi, antigiperglikemik ta'sir
Metadata source: the journal's OAI-PMH archive · Sindex does not store the full text; it links to the source.